期刊文献+

含铂方案中单铂改良为双铂联合治疗复发卵巢癌36例临床疗效观察

CLINICAL OBSERVATIAN OF CHANGING SINGLE-PLATINUM INTO DOUBLE-PLATINUM IN CONTAINING PLATINUM CHEMOTHERAPY ON THE TREATMENT OF 36 CASES OF OVARIAN CANCER
原文传递
导出
摘要 目的观察将含铂方案中的单铂改良为双铂联合治疗36例复发卵巢癌以达到等同的疗效和最低的毒副反应。方法经病理组织学或细胞学证实的36例复发卵巢癌患者,采用原来足量单铂联合方案应用一周期后出现较为严重的毒副反应而且出现中断化疗或延期化疗,即改为改良后的双铂联合的方案继续完成化疗,其中改良后的双铂联合的方案为顺铂60mg/m2的1/2量加生理盐水500ml于2h内静滴,第一天,卡铂AUC=5的1/2量加5%葡萄糖注射液500ml于2h内静滴,第八天,同时联合紫杉醇或吉西他滨等非铂类药物,每21d为1周期,至完成化疗后评价疗效及毒副反应和耐受性。结果 36例复发卵巢癌患者均可评价。CR5例,PR9例,总有效率(RR)66.7%。毒副反应评价:主要为骨髓抑制Ⅰ~Ⅱ;白细胞减少Ⅲ~Ⅳ5例,血小板减少Ⅲ~Ⅳ3例经相应处理后均可恢复,胃肠道反应极其轻微,无肝肾功能损害。结论将含铂方案中的单铂改良为双铂联合用于治疗复发卵巢癌与原来含单铂的标准方案比,毒副反应极轻,化疗依从性好,均按期完成预期的化疗周期数,从而使其疗效等同甚至优于原方案,值得一提的是,其极轻的毒副反应可明显改善生活质量,延长生存时间,极易于患者耐受。 Objective To evaluate the same efficacy and the lowest toxicity of changing single- Platinum into double - Platinum in containing Platinum chemotherapy on the treatment of 36 cases patients with recurrence ovarian cancer. Methods Selected 36 cases patients with recurrence ovarian cancer which were probved by histology or cytology,, which were treated with original containing cisplatin chemotherapy. then, the patient appears more serioue toxicity. So,we adopted the double- Platinum ehemotherapy:Cispla- tin half volume of 60mg/m^2 plus saline 500ml 2 hours ivgtt on dl and Carboplatin half volume of AUC = 5 plus glucose 500ml 2 hours ivgtt on d8. While jointed non- platinum drug as paclitaxel, gemcitabin and so on. The regimen was repeated every 21 days. The evaluation was performed after the boll cycles were finished. Results 36 patients had evaluative lesions. CR was observed in 9 case and PR in 15 cases,the tatal response rate(RR) was 66.7%. The main toxicity were myelosuppression, neuro- sensory toxicity and nausea/vomiting. There was no any death events during the treatment. Conclusion The double- platinum in containing platinum chemotherapy on the treatment of ovarian cancer has the same efficacy as original containing cisplatin chemotherapy. This therapeutic schedule can significantly improve life quality with the lowest toxicity. Its side effects is tolerable.
出处 《中国煤炭工业医学杂志》 2012年第4期526-528,共3页 Chinese Journal of Coal Industry Medicine
关键词 双铂联合 卵巢癌 疗效 毒副反应 double platinum ovarian cancer efficacy and the lowest toxicity
  • 相关文献

参考文献4

  • 1杨悦.多帕菲联合铂类治疗复发转移性卵巢癌58例临床分析[J].中华肿瘤防治杂志,2008,15(15):1176-1177. 被引量:10
  • 2孙燕主编.临床肿瘤学[M].北京:中华医学电子音像出版社,2006:148~156.
  • 3Rose PG,Smrekar M,Fusco N.A Phase II trial of weekly pa-clitaxel and every 3 weeks of carboplatin in potentially plati-num sensitive ovarian and peritoneal carcinoma[J].Gyneco-logic Oncology,2005,96:296.
  • 4Hiroshi Kagata, Tatsuya Inoue, Junichi Kato, et al. Lowfire bismuth-based dielectric ceramics for microwave use.Jpn J Appl Phys,1992,31(9B): 3152

二级参考文献4

  • 1刘军.艾素联合异环磷酰胺治疗复发性卵巢上皮癌近期疗效观察[J].中国肿瘤临床与康复,2005,12(5):417-418. 被引量:1
  • 2Vasey P. Survival and longer-term toxicity results of the SCOTROC study: docetaxel carboplatin (DC) vs. paclitaxd-carboplatin (PC) in epithelial ovarian cancer(E(X2)[J]. Proc Am Soc Clin Oncol, 2002,86 (1):19-25.
  • 3Aravantinos G, Bafalonkos D,Fountzilas G, et al. Phase Ⅱ study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer[J]. Ann Oncol,2003,14(7) : 1094-1099.
  • 4Veschraegen C F,Sittisomnong T, Kudelka A P, et al. Docetaxel for patients with paclitaxel-resistant mulovarian carcinomat[J]. J Clin Oncol,2000,18(14):2273-2739.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部